Conduit Pharmaceuticals (NASDAQ:CDT) Posts Quarterly Earnings Results

Conduit Pharmaceuticals (NASDAQ:CDT) issued its quarterly earnings results on Friday. The company reported ($20.33) earnings per share for the quarter, Zacks reports.

Conduit Pharmaceuticals Trading Up 15.9 %

Conduit Pharmaceuticals stock traded up $0.12 during midday trading on Friday, reaching $0.89. 4,959,941 shares of the company were exchanged, compared to its average volume of 1,016,669. The firm’s 50-day simple moving average is $2.03 and its 200-day simple moving average is $7.20. Conduit Pharmaceuticals has a 1 year low of $0.73 and a 1 year high of $392.00.

Conduit Pharmaceuticals Company Profile

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.